Tiziana Life Sciences welcomes liver specialist to its Scientific Advisory Board

Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.

Arun Sanyal, MD is the Professor of Medicine, Physiology and Molecular Pathology, Division of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine.

Gabriele Cerrone, Executive Chairman of the Company commented that Sanyal’s esteemed medical career covering liver cirrhosis, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) is a strategic addition to the company for further clinical development of NI-0401, a fully human anti-CD3 mAb for treatment of NASH and primary biliary cholangitis (PBC).

“Oral treatment with non-Fc binding anti-CD3 mAb with exceptional tolerability is an innovative approach for the treatment of liver inflammatory diseases such as NASH and NAFLD. I am pleased and excited to be a part of the team for clinical development of NI-0401”, said Professor Sanyal.